ArticleHealth and quality of life outcomes2022
Valuing EQ-5D-Y: the current state of play.
Article in Health and quality of life outcomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 48 citations in OpenAlex.
- The Influence of Perspective on the Valuation of the EQ-5D-Y-3L: A Comparison Using the OPUF Tool and a Discrete Choice Experiment.PharmacoEconomics · 2026Trial
- Eliciting health state utilities for open wounds in dystrophic epidermolysis bullosa.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Valuation of the EQ-5D-Y-5L Using DCE Methods That Account for Nonlinear Time Preferences.Medical decision making : an international journal of the Society for Medical Decision Making · 2026Article
- Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Value set of EQ-5D-Y-3L for Hong Kong.Health and quality of life outcomes · 2026Article
- EQ-5D(-Y) Valuation from Adult and Child Perspectives: Where Does the Empirical Evidence Leave Us and How Should We Proceed?PharmacoEconomics · 2026Review
- Valuing health states for infants and toddlers: challenges and methodological considerations in EQ-TIPS preference elicitation.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Improving Collaborative Engagement in Health State Valuation: A Scoping Review of Current Practices and Emerging Recommendations.PharmacoEconomics · 2026Review
- Exploring valuation of a modified EQ-5D-Y-3L adapted for 2-4 year olds: a think-aloud study.Health and quality of life outcomes · 2025Article
- Psychometric comparison of CHU9D and PedsQL 4.0 proxy version administered to parents of children with congenital colorectal conditions in Australia.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Article
- Eliciting and Anchoring Health State Preferences Using Discrete Choice Experiments Among Adults, Adolescents, and Children.PharmacoEconomics · 2025Article
- Measuring and Valuing Health Using EuroQol Instruments: New Developments 2025 and Beyond.Applied health economics and health policy · 2025Review
- A scoping review of challenges in pediatric health technology assessments with a focus on pharmaceutical interventions.International journal of technology assessment in health care · 2025Article
- An Australian Value Set for the EQ-5D-Y-3L.Health and quality of life outcomes · 2025Article
- Do the Age of Children and Parental Status Matter in Valuing the Child Health Utility 9D (CHU9D)?PharmacoEconomics · 2025Article
- Findings from a roundtable discussion with Pakistani stakeholders on measuring and valuing health and health-related quality of life for children and adolescents.Health and quality of life outcomes · 2025Article
- Health state utilities associated with invasive pneumococcal disease, pneumonia, and recurrent acute otitis media in young children.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Modernizing Newborn Screening in the Genomic Era: Importance of Health-Related Quality of Life.PharmacoEconomics - open · 2024Article
- Proxy Preferences and the Values of Children's Health States.PharmacoEconomics · 2024Article
- Validation of the EQ-5D-Y-5L parent-proxy version among children with juvenile idiopathic arthritis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor nearly a decade, value sets for the EQ-5D-Y were not available, reflecting challenges in valuing child HRQoL. A methodological research programme led to publication of a valuation protocol in 2020, which was rapidly taken up by local study teams. By the end of 2022, between 11 and 17 EQ-5D-Y value sets will be available, more than for any other child HRQoL measure. It is timely to review the experience of those using the protocol to identify early learnings and remaining issues where more research is needed.
methodsIn June 2021, the EuroQol Group organised a three-day workshop, bringing together all those involved in EQ-5D-Y value set studies and related methodological research concerning EQ-5D-Y and valuation. Workshop discussions were captured by note taking and recording all sessions and online chat. A narrative summary of all sessions was produced and synthesised to identify points of agreement and aspects of methods where uncertainty remains.
resultsThere was broad agreement that DCE is working well as the principal valuation method. However, the most appropriate means of anchoring the latent scale values produced by DCE remains unclear. Some studies have deviated from the protocol by extending the number of states included in TTO tasks, to better support modelling of DCE and TTO. There is ongoing discussion about the relative merits of alternative variants of TTO and other methods for anchoring. Very few studies have consulted with local end-users to gauge the acceptability of methods used to value EQ-5D-Y.
conclusionsPriority areas for research include testing alternative methods for anchoring DCE data; exploring the preferences of adolescents; and scale differences in values for EQ-5D-Y and adult EQ-5D states, and implications of such differences for the use of EQ-5D-Y values in HTA. Given the normative elements of the protocol, engaging with HTA bodies and other local users should be the first step for all future value set studies. Value sets undertaken to date are for the three-level EQ-5D-Y. However, the issues discussed in this paper are equally relevant to valuation of the five-level version of EQ-5D-Y; indeed, similar challenges are encountered valuing any measure of child HRQoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.